13. Should Your ASP Include Anti-Fungals?: Pro
Session: Interactive Session: Stewardship: Best Drivers of Change Debate
Wednesday, October 3, 2018: 2:04 PM
Room: N 24
Samuel L. Aitken, PharmD, Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX

Samuel L. Aitken, PharmD received his pharmacy degree from the University at Buffalo School of Pharmacy and Pharmaceutical Sciences in 2011. He completed his pharmacy practice residency at Yale-New New Haven Hospital and an infectious diseases pharmacotherapy fellowship at the University of Houston / Baylor St. Luke’s Medical Hospital under Dr. Kevin Garey. Dr. Aitken is a clinical pharmacy specialist in infectious diseases and infectious diseases pharmacy residency program director at The University of Texas MD Anderson Cancer Center and faculty at the Center for Antimicrobial Resistance and Microbial Genomics (CARMiG) at the UTHealth McGovern Medical School. Dr. Aitken's research is focused on the epidemiology, treatment, and molecular mechanisms of resistance in multidrug-resistant bacterial infections in patients with hematologic malignancy. In addition to these roles, Dr. Aitken is the founding chair of the Antimicrobial Stewardship in Cancer Consortium (ASCC), a group dedicated to advancing antimicrobial stewardship research and practice in cancer patients.


Disclosures:

S. L. Aitken, Shionogi: Scientific Advisor , Consulting fee . Medicines Company: Scientific Advisor , Consulting fee . Merck & Co.: Scientific Advisor , Consulting fee .

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.